TY - JOUR
T1 - Urological complications following use of recombinant human bone morphogenetic protein-2 in anterior lumbar interbody fusion Presented at the 2012 Joint Spine Section Meeting ; Clinical article
AU - Lubelski, Daniel
AU - Abdullah, Kalil G.
AU - Nowacki, Amy S.
AU - Alvin, Matthew D.
AU - Steinmetz, Michael P.
AU - Chakka, Srita
AU - Li, Yumeng
AU - Gajewski, Nicholas
AU - Benzel, Edward C.
AU - Mroz, Thomas E.
PY - 2013/2
Y1 - 2013/2
N2 - Object. The goal of this study was to compare the urological complications in patients after anterior lumbar interbody fusion (ALIF) with and without the use of recombinant human bone morphogenetic protein-2 (rhBMP-2). Methods. The authors retrospectively reviewed the medical records of all patients who underwent ALIF with and without rhBMP-2 between January 2002 and August 2010. Patient demographic, operative, and complication information was analyzed. Male patients who underwent ALIF between L-4 and S-1 were contacted to assess postoperative urological complications. Results. Of the 110 male patients who underwent ALIF and were included in this study, 59 were treated with rhBMP-2 and 51 did not receive rhBMP-2. The mean follow-up duration was 17.5 months for the rhBMP-2 group and 30.8 months for the control group. No difference was found regarding the total number of urological complications in the rhBMP-2 group versus the control group (22% vs 20%, respectively; p = 1.0) or for retrograde ejaculation specifically (8% vs 8%, respectively; p = 1.0). Conclusions. In this study, the use of rhBMP-2 with ALIF surgery was not associated with an increased incidence of urological complications and retrograde ejaculation when compared with control ALIF without rhBMP-2. Further prospective analyses that specifically look at these complications are warranted.
AB - Object. The goal of this study was to compare the urological complications in patients after anterior lumbar interbody fusion (ALIF) with and without the use of recombinant human bone morphogenetic protein-2 (rhBMP-2). Methods. The authors retrospectively reviewed the medical records of all patients who underwent ALIF with and without rhBMP-2 between January 2002 and August 2010. Patient demographic, operative, and complication information was analyzed. Male patients who underwent ALIF between L-4 and S-1 were contacted to assess postoperative urological complications. Results. Of the 110 male patients who underwent ALIF and were included in this study, 59 were treated with rhBMP-2 and 51 did not receive rhBMP-2. The mean follow-up duration was 17.5 months for the rhBMP-2 group and 30.8 months for the control group. No difference was found regarding the total number of urological complications in the rhBMP-2 group versus the control group (22% vs 20%, respectively; p = 1.0) or for retrograde ejaculation specifically (8% vs 8%, respectively; p = 1.0). Conclusions. In this study, the use of rhBMP-2 with ALIF surgery was not associated with an increased incidence of urological complications and retrograde ejaculation when compared with control ALIF without rhBMP-2. Further prospective analyses that specifically look at these complications are warranted.
KW - Anterior lumbar interbody fusion
KW - Bone morphogenetic protein
KW - Functional neurosurgery
KW - Recombinant human bone morphogenetic protein-2
KW - Retrograde ejaculation
KW - Urological complication
UR - http://www.scopus.com/inward/record.url?scp=84873695104&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873695104&partnerID=8YFLogxK
U2 - 10.3171/2012.11.SPINE12389
DO - 10.3171/2012.11.SPINE12389
M3 - Article
C2 - 23231356
AN - SCOPUS:84873695104
SN - 1547-5654
VL - 18
SP - 126
EP - 131
JO - Journal of Neurosurgery: Spine
JF - Journal of Neurosurgery: Spine
IS - 2
ER -